Atlanta, Ga. – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantly higher levels of treatment satisfaction after three infusions with TYSABRI® (natalizumab) when compared to multiple sclerosis (MS) therapies used previously. The...
Latest News
EAST LANSING, Mich. – Researchers at Michigan State University have teamed up to create a new way to image immune cells in living subjects that could enable new treatment opportunities and better outcomes for patients with Type 1 diabetes. In particular, the new approach could help bolster the success of...
WEST CHESTER, Pa. & ISTANBUL – Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu). Eczacıbaşı-Monrol entered the theranostic market in 2019...
ROCHESTER, Minn. — A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression. Results from a phase 3 clinical trial, published in the New England Journal...
MIAMI, FLORIDA – CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities. That’s the conclusion of a five-year analysis of results from the U.S. Lymphoma CAR-T Cell Consortium, a group of 17 academic cancer...
Malaga, Spain – The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary specialists, identifying a mutation that alters Alzheimer’s disease progression. This work, published in Journal of Alzheimer’s Disease,...
Durham, England – Retired rugby players who have suffered multiple concussions have higher levels of certain proteins in their blood, which may make them more prone to developing diseases such as motor neurone disease (MND), according to a new study. The research, led by Durham University, shows that it may...
NORWALK, Conn. — The Multiple Myeloma Research Foundation (MMRF) announced today a new publication on the CoMMpassSM study in Nature Genetics that defines distinct subtypes and identifies high-risk genetic markers of multiple myeloma. These CoMMpass data represent the largest and most complete clinical and molecular dataset in multiple myeloma. “Despite...
Cologne, Germany – The Federal Joint Committee (G-BA), the highest decision-making body in the German health care system, commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess a total of 10 drugs for the treatment of multiple sclerosis (MS): The immunomodulators cladribine, dimethyl fumarate, ozanimod, ponesimod,...
Vienna, Austria – The underlying cause of MS has not yet been fully clarified, but a connection with the Epstein-Barr virus (EBV) has long been suspected. In most patients who develop MS, specific immune responses against EBV are detectable, which are also directed against certain structures of the central nervous...